TGTX 12.81 Tg Therapeutics $TGTX Hit a 52 week high of

New Post Public Reply Private Reply Replies (0) Message Board

Nov 12, 2014 at 2:54 PM

TGTX 12.81 Tg Therapeutics $TGTX Hit a 52 week high of 12.88 Closing the day 09:42 at 12.81 -0.10 -0.77% With a day low of 12.64 and a total volume of 28,808.

TGTX Recent Posts: http://investorshangout.com/TG-Therapeutics-Inc-TGTX-64219/

TGTX Tg Therapeutics Recent Headline News

Nasdaq stocks posting largest percentage increases
AP - Tue Nov 11, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
ICUI: 84.01 (+3.14), OREX: 5.83 (+0.79), PCMI: 8.90 (unch), CYAN: 6.00 (-0.06), ACHN: 14.46 (+1.98), TGTX: 13.83 (+0.92), AGIO: 87.18 (+5.27), LIOX: 5.41 (-0.02), SAJA: 5.90 (-0.35), PLNR: 6.95 (+0.14)

TG Therapeutics' (TGTX) CEO Michael Weiss on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Nov 11, 2:03PM CST

TGTX: 13.83 (+0.92)

TG Therapeutics net loss worsens in Q3
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 11:10AM CST

TGTX: 13.77 (+0.86)

TG Therapeutics posts 3Q loss
Automated Insights - Tue Nov 11, 4:11AM CST
NEW YORK (AP) _ TG Therapeutics Inc. (TGTX) on Tuesday reported a loss of $17.5 million, or 51 cents per share, in its third quarter.
TGTX: 13.77 (+0.86)

TG Therapeutics misses by $0.19
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 4:12PM CST

TGTX: 13.77 (+0.86)

TG Therapeutics, Inc. Announces Third Quarter 2014 Financial Results and Business Update
GlobeNewswire - Mon Nov 10, 3:20PM CST
TG Therapeutics, Inc. (Nasdaq:TGTX), an innovative clinical-stage biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for cancer and autoimmune diseases, today announced its results for the third quarter ended September 30, 2014 and recent company developments.
TGTX: 13.75 (+0.84)

TG Therapeutics reports November 11
Seeking Alpha - at Seeking Alpha - Fri Nov 07, 3:10PM CST

TGTX: 13.75 (+0.84)

TG Therapeutics, Inc. to Host Conference Call on Third Quarter 2014 Financial Results and Business Update
GlobeNewswire - Fri Nov 07, 3:00PM CST
TG Therapeutics, Inc. (Nasdaq:TGTX), announced today that a conference call will be held on Tuesday, November 11, 2014 at 8:30am ET to discuss results for the third quarter of 2014 and provide a business outlook for the remainder of the year. Michael Weiss, Executive Chairman and Interim Chief Executive Officer, will host the call.
TGTX: 13.83 (+0.92)

TG Therapeutics, Inc. Announces Data Presentations at the Upcoming 56th American Society of Hematology Annual Meeting
GlobeNewswire - Thu Nov 06, 8:45AM CST
Combination of TG-1101, the Company's Novel Glycoenginereed Anti-CD20 Monoclonal Antibody and TGR-1202, the Company's Once Daily PI3K Delta Inhibitor to be Highlighted in Oral Presentation
TGTX: 13.83 (+0.92)

Strong On High Relative Volume: TG Therapeutics (TGTX)
at The Street - Mon Oct 27, 9:00AM CDT
Trade-Ideas LLC identified TG Therapeutics (TGTX) as a strong on high relative volume candidate
TGTX: 13.83 (+0.92)

Ligand Earns Milestone Payment on EU Approval of Noxafil - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 02, 12:00PM CDT
Ligand Pharmaceuticals Incorporated (LGND) earned a $550,000 milestone payment from partner Merck (MRK) on the EU approval of Noxafil (posaconazole) for infusion.
MRK: 59.24 (-0.13), TGTX: 13.83 (+0.92), LGND: 57.41 (+0.51), AMGN: 162.05 (-0.37)

TG Therapeutics reports exercise of its option to license the global rights to TGR-1202
M2 - Wed Sep 24, 6:17AM CDT
Biopharmaceutical company TG Therapeutics (NasdaqCM :TGTX) said on Tuesday that it has exercised its option to license the global rights to TGR-1202 from Rhizen Pharmaceuticals.
TGTX: 13.83 (+0.92)

Rhizen Pharmaceuticals Announces Out-licensing Agreement for TGR-1202, a Novel Next Generation PI3K-delta Inhibitor
GlobeNewswire - Tue Sep 23, 9:39AM CDT
Rhizen Pharmaceuticals S.A. today announced an out-licensing agreement for TGR-1202, a novel next generation PI3K-delta inhibitor. TG Therapeutics exercised its option for early conversion to a licensing agreement from a 50:50 joint venture partnership.
TGTX: 13.82 (+0.91)

TG Therapeutics Announces Exercise of License Option for Its Novel, Next Generation PI3K-Delta Inhibitor, TGR-1202
GlobeNewswire - Tue Sep 23, 6:30AM CDT
TG Therapeutics, Inc. (Nasdaq:TGTX) today announced that it has exercised its option to license the global rights to TGR-1202, the Company's novel, next generation PI3K-delta inhibitor from Rhizen Pharmaceuticals, S A ("Rhizen"

. The Company and Rhizen have to date been jointly developing TGR-1202 in a 50:50 joint venture. Given the successful development of TGR-1202, TG Therapeutics elected an early exercise of the Company's license option.
TGTX: 13.82 (+0.91)

TG Therapeutics (TGTX) in Focus: Stock Gains 16.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Sep 18, 8:46AM CDT
TG Therapeutics (TGTX) was a big mover last session, with shares rising over 16% on the day.
ICUI: 84.01 (+3.14), ABAX: 53.79 (+0.29), TGTX: 13.82 (+0.91), EGRX: 12.97 (-0.56)

TG Therapeutics Announces Special Protocol Assessment (SPA) Agreement With the FDA for Its First Phase 3 Clinical Trial of TG-1101 (ublituximab) in Combination With Imbruvica(R) (ibrutinib) for Patients With Previously Treated Chronic Lymphocytic Leukemia
GlobeNewswire - Mon Sep 15, 6:08AM CDT
Overall Response Rate (ORR) to be the Primary Endpoint to Support Accelerated Approval with Progression-Free Survival (PFS) to Support Full Approval
TGTX: 13.82 (+0.91)

UPDATE -- TG Therapeutics, Inc. to Present at the 16th Annual Rodman & Renshaw Global Investment Conference
GlobeNewswire - Mon Sep 08, 3:28PM CDT
In a release issued earlier today by TG Therapeutics, Inc. (Nasdaq:TGTX), please note the company's scheduled presentation time has changed to 1:15 PM ET, from 1:40 PM ET previously. The updated release follows:
TGTX: 13.82 (+0.91)

TG Therapeutics, Inc. to Present at the 16th Annual Rodman & Renshaw Global Investment Conference
GlobeNewswire - Mon Sep 08, 9:12AM CDT
TG Therapeutics, Inc. (Nasdaq:TGTX), an innovative, clinical-stage biopharmaceutical company today announced that Michael Weiss, the Company's Interim Chief Executive Officer, will be presenting at the 16 Annual Rodman & Renshaw Global Investment Conference being held at the New York Palace Hotel. Mr. Weiss' presentation is scheduled to take place on Tuesday, September 9, 2014 at 1:40 PM ET. A live webcast of this presentation will be available on the Events page, located within the Investors & Media section of the Company's website at www.tgtherapeutics.com.
TGTX: 13.78 (+0.87)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Business Leaders Push for Justice Reform Policy

Business stepping up to bat for justice reform? Yeah, that’s what's shaking over in Washington, D.C. this Constitution Day. We're seeing a gathering of senior business execs, policymakers, and public safety advocates, intent on driving judicial reform in the U.S. Usually, the suits in these rooms talk about profit margins and quarterly results, but this time they're...

Baystate Noble Plans Major ED Expansion for Future Needs

A Trusted Name in Healthcare Steps Up When a healthcare player like Baystate Health decides to jump into the deep end with an expansion project, you know they're not just doodling on napkins. With a legacy stretching back to 1883, Baystate Health, anchored deeply in western New England, isn't just expanding for fun—it's a move to cement its position as a crucial...

Jeen's Real-Time AI Cost Management Unveiled

Unmasking the Ghosts in AI Expenses Enterprises are thrashing around in the digital ocean of AI, yet many still can't see what's draining their coffers. It's not just the savant data scientists racking up the charges; it's every automated agent chipping away at resources—unnoticed until the bill finally lands. That's where Jeen is stepping in, flipping the script on...

Jamba's Cloud Whip: A Bold Blend in Beverage Scene

An Unexpected Shake-Up in the Beverage Game Folks, brace yourselves because Jamba's making some bold moves. I remember a time when a smoothie was just a smoothie, but now, they're stacking up a new deck with this fancy thing they're calling 'Cloud Whip'. It's basically a way to slap some extra protein onto your drink, with 10 grams coming at you like a freight train...

SCO at 25: China's Strategic Push for Regional Growth

There's a new beat coming out of Central Asia, and it's resonating all the way from China's boardrooms to the barren landscapes of the Gobi Desert. With the Shanghai Cooperation Organization (SCO) celebrating its 25th anniversary, we're witnessing a pivot from a security-centric setup to a full-blown economic collaboration machine. The Landscape of SCO's Evolution Look,...

Innventure Faces Class Action Over Alleged Deception

Unpacking the Innventure Debacle Innventure, Inc. (NASDAQ:INV) seems to have landed itself in hot water, and not the relaxing kind. The revelation that its grand AI data center project in Ontario might never have existed has stirred up quite a storm among shareholders. This isn't just some run-of-the-mill oversight. We're talking about allegations of concocted stories...

Kevin Hart & Pragmatic Play Revamp Live Casino Scene

Where Comedy Meets Chances You've got Kevin Hart, larger than life, and then you've got Pragmatic Play—a key player in iGaming. Put them together and you've got an event that might turn the usual casino lights into a full-blown spotlight. They're not just throwing dice, they're shaking up the market with potential way beyond what meets the eye. Okay, so here's the...

Elbphilharmonie Hamburg: 10th Anniversary Marks Milestone

Elbphilharmonie's Impact on Hamburg's Cultural Landscape Here we are, staring down the first decade of the Elbphilharmonie, and boy, if that isn't a testament to sticking your neck out for culture, I don't know what is. Opened back on January 11, 2017, this concert hall started as just another controversial project, folks wagging tongues about costs and ambition. But...

RealityMine Appoints CPO Amidst Strong Growth Momentum

Pushing the Boundaries of Behavioral Data When a company like RealityMine posts a whopping 75% year-over-year revenue bump, you know they're not here to mess around. Enter Soumya Bijjal, a seasoned pro stepping in as their inaugural Chief Product Officer. This isn't just about adding to the C-suite boys' club; it's about locking in on a goldmine of behavioral data that's...

Comcast Unveils Game-Changing Next-Gen Video AI

Comcast Technology Solutions Takes a Big Swing Well, Comcast Technology Solutions (CTS) is stepping up to the plate with an offering that just might knock it out of the park for broadcasters and content creators. They're rolling out an ambitious suite of AI-powered video workflow tools that could potentially redefine how operators handle their media libraries. The buzz is...